Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.

The COVID-19 pandemic is having a devastating effect on global business, and biopharma companies are not excluded. A report by GlobalData found that the market capitalization for the majority of top 20 global pharma companies declined in the first quarter of 2020 versus Q4 2019, with a combined decrease of 7.9 percent.

The long-awaited and massively hyped initial public offering (IPO) of Moderna Therapeutics hit the market.